Now, after a presentation at the 13D Monitor Active-Passive Investor Summit by Starboard's CEO Jeffrey Smith on Oct. 22, ...

Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

At an investor summit in New York on Tuesday, activist investor Starboard called out Pfizer's PFE board of directors to take ...

Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...

The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.

Newcomers will be plugging into the stock while its forward-looking dividend yield stands at 5.8%. There's a decent chance ...

Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...